title: Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
abstract: The study evaluated the efficacy of bevacizumab combined with a taxane-based treatment for advanced breast cancer.
  
  
  
  In this non-randomized phase II study 65 patients received 10 mg/kg bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m2docetaxel (days 1 and 15, q4w) or 90 mg/m2paclitaxel (days 1,8 and 15, q4w) i.v. until disease progression, maximal response, unacceptable toxicity or the withdrawal of consent. Patients without progression continued bevacizumab at 15 mg/kg i.v. (q3w) alone, or with endocrine therapy. (NCT00979641).
  
  
  
  Progression-free survival was 11.3 months (95% confidence interval=9.7-16.0 months) and overall survival was 35.1 months (95% confidence interval=22.2-50.3 months). More than half of the patients (62%) responded at least partially. Bevacizumab-related serious adverse events occurred in 10.8% patients and one patient died because of gastrointestinal perforation.
  
  
  
  Treating advanced breast cancer with a bevacizumab-containing regimen as the first-line cytotoxic treatment resulted in excellent response rates and long survival.
authors.affiliation: Department of Oncology, School of Medicine, University of Tampere, Tampere, Finland leena.tiainen@pshp.fi.|Department of Oncology, Tampere University Hospital, Tampere, Finland.
authors.forename: Leena
authors.initials: L
authors.lastname: Tiainen
authors.affiliation: Department of Oncology, School of Medicine, University of Tampere, Tampere, Finland.|Department of Oncology, Tampere University Hospital, Tampere, Finland.
authors.forename: Minna
authors.initials: M
authors.lastname: Tanner
authors.affiliation: Department of Oncology, Turku University Central Hospital, Turku, Finland.
authors.forename: Outi
authors.initials: O
authors.lastname: Lahdenperä
authors.affiliation: Department of Oncology, Turku University Central Hospital, Turku, Finland.
authors.forename: Pia
authors.initials: P
authors.lastname: Vihinen
authors.affiliation: Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
authors.forename: Arja
authors.initials: A
authors.lastname: Jukkola
authors.affiliation: Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
authors.forename: Peeter
authors.initials: P
authors.lastname: Karihtala
authors.affiliation: Department of Oncology, Tampere University Hospital, Tampere, Finland.
authors.forename: Niina
authors.initials: N
authors.lastname: Paunu
authors.affiliation: Oy 4Pharma Ltd, Turku, Finland.
authors.forename: Teppo
authors.initials: T
authors.lastname: Huttunen
authors.affiliation: Department of Oncology, School of Medicine, University of Tampere, Tampere, Finland.|Department of Oncology, Tampere University Hospital, Tampere, Finland.
authors.forename: Pirkko-Liisa
authors.initials: PL
authors.lastname: Kellokumpu-Lehtinen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab; D017239:Paclitaxel
keywords: Advanced breast cancer; bevacizumab; first-line chemotherapy; maintenance therapy; phase II study; taxanes